| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
3.69(M) |
| Last
Volume: |
900 |
Avg
Vol: |
59,812 |
| 52
Week Range: |
$0.06 - $0.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Levy Harold J |
Director |
– • – |
2010-02-18 |
4 |
A |
$0.00 |
$0 |
I/I |
116,535 |
166,535 |
|
- |
|
| Delcampo Ralph |
EVP-Technical Operations |
• – – |
2010-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,665 |
148,122 |
|
- |
|
| Buchalter Jeffrey H |
CEO & President |
• • – |
2010-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
37,994 |
529,259 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,559 |
82,524 |
|
- |
|
| Horak Ivan D |
EVP,R&D, CSO |
• – – |
2010-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,465 |
140,476 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
13,932 |
128,096 |
|
- |
|
| Horak Ivan D |
EVP, R&D, Chief Scientific Off |
• – – |
2010-01-17 |
4 |
D |
$10.91 |
$109,678 |
D/D |
(10,053) |
124,011 |
|
- |
|
| Horak Ivan D |
EVP, R&D, Chief Scientific Off |
• – – |
2010-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,666 |
134,064 |
|
- |
|
| Delcampo Ralph |
EVP-Technical Operations |
• – – |
2010-01-17 |
4 |
D |
$10.91 |
$109,678 |
D/D |
(10,053) |
135,457 |
|
- |
|
| Delcampo Ralph |
EVP-Technical Operations |
• – – |
2010-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,666 |
145,510 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-01-17 |
4 |
D |
$10.91 |
$12,994 |
D/D |
(1,191) |
74,925 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,333 |
76,116 |
|
- |
|
| Buchalter Jeffrey H |
CEO & President |
• • – |
2010-01-17 |
4 |
D |
$10.91 |
$429,756 |
D/D |
(39,391) |
491,265 |
|
- |
|
| Buchalter Jeffrey H |
CEO & President |
• • – |
2010-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
99,999 |
530,656 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-01-17 |
4 |
D |
$10.91 |
$103,056 |
D/D |
(9,446) |
114,164 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,666 |
123,610 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-01-05 |
4 |
D |
$10.77 |
$44,771 |
D/D |
(4,157) |
123,610 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
127,767 |
|
- |
|
| Buchalter Jeffrey H |
CEO & President |
• • – |
2009-12-22 |
4 |
D |
$10.77 |
$114,539 |
D/D |
(10,635) |
530,656 |
|
- |
|
| Buchalter Jeffrey H |
CEO & President |
• • – |
2009-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
541,291 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2009-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
76,116 |
|
- |
|
| Buchalter Jeffrey H |
Chairman, CEO & President |
• • – |
2009-11-23 |
4 |
D |
$10.37 |
$169,674 |
D/D |
(16,362) |
541,291 |
|
- |
|
| Buchalter Jeffrey H |
Chairman, CEO & President |
• • – |
2009-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,000 |
557,653 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2009-11-23 |
4 |
D |
$10.37 |
$11,023 |
D/D |
(1,063) |
127,767 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2009-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
128,830 |
|
- |
|
394 Records found
|
|
Page 9 of 16 |
|
|
